SEPN vs HRMY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SEPN · Septerna$38.61 ▼ 1.51%
HRMY · Harmony Biosciences$32.59 ▼ 1.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SEPN +35.4%
- HRMY -7.6%
Head to head
| Metric | SEPN | HRMY |
|---|---|---|
| Price | $38.61 | $32.59 |
| Change today | ▼ 1.51% | ▼ 1.18% |
| Market cap | $1.84B | $1.91B |
| Return, 3 months | -4.7% | -15.4% |
| Return, year to date | +38.5% | -12.9% |
| Return, 1 year | +51.1% | -5.0% |
| P/E (TTM) | – | 10.8 |
| P/B | 4.3 | 1.8 |
| P/E percentile vs own 5y | 38th | 17th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -12.2% | +12.3% |
| Net profit growth (YoY) | -425.3% | -5.2% |
| Gross margin | – | 74.0% |
| Operating margin | -76.2% | 22.2% |
| Net margin | -61.3% | 18.1% |
| Return on equity | -14.4% | 18.7% |
| Analyst target vs. price | +52.8% | +45.8% |
| Analyst buy share | 100% | 63% |
| RSI (14) | 40 | 32 |
| 30-day volatility | 72.0% | 42.9% |
| Max drawdown, 1 year | -26.2% | -34.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HRMY is the largest of the group by market value.
- SEPN has returned the most over the past year.
- HRMY is growing revenue fastest.
- HRMY keeps the most profit per dollar of sales.
- HRMY has been the calmest stock over the last 30 days.